Exercise of Options and Total Voting Rights

Destiny Pharma PLC

26 April 2023

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 26 April 2023 - Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has issued and allotted 804,856 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by former employees.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 3 May 2023 ("Admission").

Following Admission, the Company will have a total of 95,263,917 Ordinary Shares in issue. Shareholders may use this figure of 95,263,917 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

Optimum Strategic Communications 
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
[phone]
[e-mail]

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
[phone]

Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
[phone]

MC Services AG
Anne Hennecke / Andreas Burckhardt
[phone]

Stern IR - US
Janhavi Mohite
[phone]
[e-mail]

 

END